ENAMINE/ADDEX
Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’s small molecule CNS drug discovery programs.
The collaboration is established under a Full Time Equivalent (FTE) model, serving optimally the various research programs, with Addex Therapeutics owning all resulting Intellectual Property Rights.
“Over many years of collaboration, we have witnessed the enabling technology developments of Enamine in areas such as parallel chemistry, analytics, ADME and biophysical screening methods,” commented Jean-Philippe Rocher, Co-Head of Discovery and Member of the Executive Management of Addex Therapeutics. “We have been particularly impressed with Enamine’s sharp focus on the needs of our programs and their commitment to customer service. The immediate access we have to a broad chemical space coupled with Enamine’s large synthetic toolbox has a direct positive impact to advance our lead finding activities.”
Michael Bossert, Head Strategic Alliances at Enamine added: “In the world of turmoil of last year, Enamine was adequately adapting to the challenges, allowing another year of record revenue achievement. Our continued innovation in chemistry and our unique stock of over 225,000 building blocks available to our chemists benefit to our customers and their discovery of the next stream of medicines.” He continued: “We are delighted to extend our collaboration with Addex Therapeutics; we are moving forward into 2021 with a great excitement.”
About Enamine Ltd. www.enamine.net
Established in Kyiv in 1991, Enamine is a global leading designer and largest producer of building blocks (225,000+), fragments (172,000+) and screening libraries (2.5M+ compounds). Enamine provides expertise in advanced organic synthesis, library synthesis, medicinal chemistry. In 2011 Enamine established a pre-clinical service unit including ADME, in-vivo PK studies and High Throughput Screening under the brand name “Bienta”, allowing the company to tackle since that time fully integrated or à-la-carte research programs.
About Addex Therapeutics https://www.addextherapeutics.com
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex is listed on the NASDAQ Capital Market and is trading under the ticker symbol "ADXN".
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uptime Institute Announces Five Data Center Predictions Report for 202613.1.2026 12:04:00 CET | Press release
As corporate AI moves beyond pilots and experimentation, infrastructure designers and operators face a series of big challenges spanning power, resiliency, sustainability and automation Uptime Institute today announced the release of its Five Data Center Predictions for 2026 looking beyond the more obvious trends of 2026 and examining some of the latest developments and challenges shaping the digital infrastructure industry. The 2026 predictions focus on the continued growth of the industry and related challenges, while also recognizing AI as a powerful, transformative accelerant to growth. While AI is the key driver for a wave of investment that will underpin digital infrastructure for decades to come, the speed and ultimate size of the build-outs are unclear at this time. “Critical digital infrastructure continues to expand strongly,” said Andy Lawrence, Executive Director of Research, Uptime Institute. “At the same time, our research shows uncertainty about how AI will reshape deman
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference13.1.2026 12:00:00 CET | Press release
Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company’s transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton’s tyrosine kinase (BTK) inhibitors, as well as foundational hematology assets: sonrotoclax, a next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor that received its first global regulatory approvals on December 30, and BGB-16673, a potentially first-in-class and best-in-class BTK chimeric degradation activation compound (CDAC). I
BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research13.1.2026 12:00:00 CET | Press release
Partnership enables AI-assisted research while preserving BlueMatrix’s governance-first approach to integrating AI into regulated research environments. BlueMatrix, the global leader in capital markets content publishing technology, backed by Thoma Bravo, today announced a partnership with Perplexity to bring AI-enabled research and discovery to institutional investors using BlueMatrix’s governed, entitlement-aware framework. The partnership brings entitled broker research to Perplexity Enterprise users, enabling buy-side professionals to query their subscribed research content, alongside Perplexity’s broader capabilities, including real-time financial data, earnings transcripts, and deep research tools. Investment professionals and researchers can use natural language to surface relevant insights without changing existing data ownership, entitlements, or compliance structures. As buy-side teams increasingly turn to AI tools for research synthesis, a formal integration through BlueMatr
Vaudoise Becomes First Swiss Insurer to Go-Live with Guidewire Cloud Platform13.1.2026 11:21:00 CET | Press release
Vaudoise and Guidewire (NYSE: GWRE) have announced that Vaudoise has become the first Swiss insurer to go-live on Guidewire Cloud Platform. The company has successfully implemented Guidewire ClaimCenter and is currently integrating Guidewire PolicyCenter. By adopting Guidewire Cloud Platform, Vaudoise joins a global community of insurers focusing on insurance excellence with core modernization from a scalable, secure and rapidly updatable cloud delivery model. Arno Suess, Head of P&C Claims at Vaudoise, said: “We are very proud of this milestone, which sets a new benchmark for our industry. With Guidewire Cloud Platform, we can now process motor insurance claims faster, with greater automation and fully digital processes. The result: faster decisions, more transparency, and a seamless experience for customers during critical moments in their lives.” Mathias Grobet, EMEA VP at Guidewire, said: “Vaudoise is well-known for its customer focus, operational excellence and agility – qualities
Ant International Powered Over 2 Billion Transactions in its Core Emerging Markets in 2025, Expanding AI Payments and Digital Commerce Tools for Inclusive Growth13.1.2026 11:15:00 CET | Press release
150 million merchants across the world from Kuala Lumpur to London leverage Ant International’s solutions to reach local and global customers.In its main emerging markets, clients in Southeast Asia, South Asia, the Middle East and Latin America, including the SME sectors, recorded strong uplift through digital payments, cross-border commerce and banking solutions in 2025. Ant International supported over 2 billion digital cross-border transactions in 2025 for merchants in its core emerging markets including Southeast Asia (SEA), South Asia, the Middle East and Latin America (LATAM), as the company builds out a broader range of AI-powered digital financial and commerce solutions tailored to these regions’ diverse needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113850175/en/ Alipay+ now connects more than 1.8 billion user accounts across 40 international payment partners to merchants across more than 100 markets Ant I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom